Citizens lowered the firm’s price target on Crinetics (CRNX) to $95 from $97 and keeps an Outperform rating on the shares. Palsonify’s launch appears strong with expanding prescriber adoption and improving reimbursement trends, supporting confidence in 2026 revenue expectations above consensus, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Crinetics reports Q1 EPS ($1.23), consensus ($1.24)
- Analyst Maintains Buy on Palsonify Amid Strong Global Growth Prospects Despite Trimmed Price Target to $90
- Crinetics price target raised to $97 from $96 at Citizens
- Crinetics’ Palsonify approved by European Commission for acromegaly
- ALX Oncology appoints Jeff Knight as chief development, operating officer